In a molecular study of clinical samples from the clinical trial of Tan et al., using azacitidine and panobinostat for MDS and AML [62], Liu et al. analyzed mRNA of Nur77, p15 and p21 in the clinical patient samples, and found that restored levels of Nur77 and p21 correlated with clinical responses to the combination therapy [59], in concordance with other studies suggesting Nur77 as a biomarker of HDACi mediated apoptosis also in the leukemic stem cell compartment [51]. Here, NR4A1 is linked to myelodysplastic syndrome.